Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. The company offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.
Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) - Net Assets
Latest net assets as of September 2025: CN¥3.13 Billion CNY
Based on the latest financial reports, Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) has net assets worth CN¥3.13 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.07 Billion) and total liabilities (CN¥2.94 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.13 Billion |
| % of Total Assets | 51.62% |
| Annual Growth Rate | 67.92% |
| 5-Year Change | 450.25% |
| 10-Year Change | 8794.26% |
| Growth Volatility | 84.38 |
Shanghai Haoyuan Chemexpress Co. Ltd. A - Net Assets Trend (2013–2024)
This chart illustrates how Shanghai Haoyuan Chemexpress Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Haoyuan Chemexpress Co. Ltd. A (2013–2024)
The table below shows the annual net assets of Shanghai Haoyuan Chemexpress Co. Ltd. A from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.90 Billion | +14.96% |
| 2023-12-31 | CN¥2.53 Billion | +8.33% |
| 2022-12-31 | CN¥2.33 Billion | +26.98% |
| 2021-12-31 | CN¥1.84 Billion | +247.94% |
| 2020-12-31 | CN¥527.81 Million | +32.04% |
| 2019-12-31 | CN¥399.73 Million | +125.01% |
| 2018-12-31 | CN¥177.65 Million | +54.83% |
| 2017-12-31 | CN¥114.74 Million | +101.79% |
| 2016-12-31 | CN¥56.86 Million | +74.13% |
| 2015-12-31 | CN¥32.65 Million | -1.36% |
| 2014-12-31 | CN¥33.10 Million | +241.37% |
| 2013-12-31 | CN¥9.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Haoyuan Chemexpress Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10041.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥821.49 Million | 28.55% |
| Common Stock | CN¥210.96 Million | 7.33% |
| Other Comprehensive Income | CN¥221.62 Million | 7.70% |
| Other Components | CN¥1.62 Billion | 56.42% |
| Total Equity | CN¥2.88 Billion | 100.00% |
Shanghai Haoyuan Chemexpress Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Haoyuan Chemexpress Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Charter Hall Retail REIT
AU:CQR
|
$1.08 Billion |
|
Jiangsu Linyang Energy Co Ltd
SHG:601222
|
$1.08 Billion |
|
Chipbond Technology
TWO:6147
|
$1.08 Billion |
|
Beijing Toread Outdoor Product
SHE:300005
|
$1.08 Billion |
|
Babcock & Wilcox Enterprises Inc
NYSE:BW
|
$1.08 Billion |
|
Zhejiang Huafon Spandex Co Ltd
SHE:002064
|
$1.08 Billion |
|
Shenzhen Fenda Technology Co Ltd
SHE:002681
|
$1.08 Billion |
|
Beijing Yuanliu Hongyuan Electronic Technology Co Ltd
SHG:603267
|
$1.08 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Haoyuan Chemexpress Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,509,078,803 to 2,877,877,144, a change of 368,798,341 (14.7%).
- Net income of 201,590,096 contributed positively to equity growth.
- Dividend payments of 47,043,968 reduced retained earnings.
- Other comprehensive income increased equity by 221,615,454.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥201.59 Million | +7.0% |
| Dividends Paid | CN¥47.04 Million | -1.63% |
| Other Comprehensive Income | CN¥221.62 Million | +7.7% |
| Other Changes | CN¥-7.36 Million | -0.26% |
| Total Change | CN¥- | 14.70% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Haoyuan Chemexpress Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 718.63x to 4.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.09 | CN¥65.85 | x |
| 2014-12-31 | CN¥0.28 | CN¥65.85 | x |
| 2015-12-31 | CN¥0.21 | CN¥65.85 | x |
| 2016-12-31 | CN¥0.33 | CN¥65.85 | x |
| 2017-12-31 | CN¥0.61 | CN¥65.85 | x |
| 2018-12-31 | CN¥0.87 | CN¥65.85 | x |
| 2019-12-31 | CN¥1.96 | CN¥65.85 | x |
| 2020-12-31 | CN¥2.59 | CN¥65.85 | x |
| 2021-12-31 | CN¥8.93 | CN¥65.85 | x |
| 2022-12-31 | CN¥11.11 | CN¥65.85 | x |
| 2023-12-31 | CN¥11.95 | CN¥65.85 | x |
| 2024-12-31 | CN¥13.70 | CN¥65.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Haoyuan Chemexpress Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.00%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.88%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.91x
- Recent ROE (7.00%) is below the historical average (15.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 23.97% | 3.96% | 1.70x | 3.56x | CN¥1.35 Million |
| 2014 | 9.52% | 4.70% | 1.17x | 1.73x | CN¥-158.95K |
| 2015 | 26.14% | 9.28% | 1.23x | 2.28x | CN¥5.27 Million |
| 2016 | 32.19% | 15.39% | 0.75x | 2.79x | CN¥12.42 Million |
| 2017 | 13.08% | 8.63% | 0.91x | 1.67x | CN¥3.53 Million |
| 2018 | 10.37% | 6.13% | 0.99x | 1.71x | CN¥648.67K |
| 2019 | 18.37% | 17.95% | 0.75x | 1.36x | CN¥33.46 Million |
| 2020 | 24.33% | 20.22% | 0.74x | 1.62x | CN¥75.65 Million |
| 2021 | 10.48% | 19.70% | 0.41x | 1.31x | CN¥8.75 Million |
| 2022 | 8.35% | 14.26% | 0.38x | 1.55x | CN¥-38.35 Million |
| 2023 | 5.08% | 6.78% | 0.45x | 1.67x | CN¥-123.46 Million |
| 2024 | 7.00% | 8.88% | 0.41x | 1.91x | CN¥-86.20 Million |
Industry Comparison
This section compares Shanghai Haoyuan Chemexpress Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) | CN¥3.13 Billion | 23.97% | 0.94x | $1.08 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |